This multicenter, retrospective observational study will evaluate compliance an reasons for withdrawal in patients with moderate to severe active rheumatoid arthritis on treatment with intravenous RoActemra/Actemra (tocilizumab) in daily clinical practice. Data will be collected from each eligible patient over a period of 6 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01649817?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
